Target: CD8.
Clone: UCHT-4.
Specificity: Anti-CD8 In Vivo Antibody - Low Endotoxin (UCHT-4) recognizes Human CD8. Anti-Human CD8 recognizes a T-cell glycoprotein cell surface complex (Mr 32 kDa) which defines the cytotoxic/suppressor population of mature T-lymphocytes. The CD8 complex interacts with class I MHC molecules resulting in increased adhesion between CD8+ T-lymphocytes and their target cells. Binding of the CD8 antigen to Class I MHC molecules enhances T-cell activation. The cytoplasmic portion of the CD8 antigen is associated with a protein tyrosine kinase (p56lck).
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: The CD8 antigen is expressed on approximately 19-48% of normal human peripheral blood lymphocytes and > 90% of normal thymocytes. It is also present on a subset of NK cells. Subjects infected with HIV have been shown to exhibit increased levels of CD8+ lymphocytes with a continual decrease in CD4+ lymphocytes.
Background: Anti-CD8 may be used in studies of immunoregulation and T-lymphocyte mediated suppression, autoimmune disorders, immunodeficiency states and acute lymphoblastic leukemia and lymphoma.
Concentration: 1.0 - 5.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >95% by SDS-PAGE and HPLC.
Endotoxin: <1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
